- Home
- PLAY vs MESO Comparison
PLAY vs MESO Comparison
Compare PLAY & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLAY
- MESO
- Stock Information
- Founded
- PLAY 1982
- MESO 2004
- Country
- PLAY United States
- MESO Australia
- Employees
- PLAY N/A
- MESO N/A
- Industry
- PLAY Restaurants
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PLAY Consumer Discretionary
- MESO Health Care
- Exchange
- PLAY Nasdaq
- MESO Nasdaq
- Market Cap
- PLAY 1.3B
- MESO 1.1B
- IPO Year
- PLAY 1995
- MESO N/A
- Fundamental
- Price
- PLAY $38.01
- MESO $10.04
- Analyst Decision
- PLAY Buy
- MESO Strong Buy
- Analyst Count
- PLAY 8
- MESO 4
- Target Price
- PLAY $65.00
- MESO $11.50
- AVG Volume (30 Days)
- PLAY 1.1M
- MESO 204.9K
- Earning Date
- PLAY 12-03-2024
- MESO 08-28-2024
- Dividend Yield
- PLAY N/A
- MESO N/A
- EPS Growth
- PLAY N/A
- MESO N/A
- EPS
- PLAY 2.71
- MESO N/A
- Revenue
- PLAY $2,211,100,000.00
- MESO $5,902,000.00
- Revenue This Year
- PLAY $0.89
- MESO $66.05
- Revenue Next Year
- PLAY $6.97
- MESO $348.27
- P/E Ratio
- PLAY $14.04
- MESO N/A
- Revenue Growth
- PLAY 1.23
- MESO N/A
- 52 Week Low
- PLAY $29.31
- MESO $1.61
- 52 Week High
- PLAY $69.82
- MESO $12.18
- Technical
- Relative Strength Index (RSI)
- PLAY 50.72
- MESO 55.85
- Support Level
- PLAY $38.60
- MESO $8.52
- Resistance Level
- PLAY $43.73
- MESO $12.18
- Average True Range (ATR)
- PLAY 1.87
- MESO 0.63
- MACD
- PLAY -0.18
- MESO 0.17
- Stochastic Oscillator
- PLAY 16.13
- MESO 57.96
About PLAY Dave & Buster's Entertainment Inc.
Dave & Buster's Entertainment Inc owns and operates nearly a hundred entertainment and dining establishments in the United States where customers can eat, drink, play games, and watch televised sports. Each store offers a full menu of entries and appetizers, a complete selection of alcoholic and non-alcoholic beverages, and an extensive assortment of entertainment attractions centered around playing games and watching live sports and other televised events. It derives maximum revenue from Entertainment.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.